IS2671B - Rauðkornavaki í undirblóðríkisskömmtum - Google Patents

Rauðkornavaki í undirblóðríkisskömmtum

Info

Publication number: IS2671B
Authority: IS; Iceland
Prior art keywords: epo; tissue; endothelial; derivatives; stimulating
Prior art date: 2002-07-26

Application number

IS7633A

Other languages

English (en)

Other versions

IS7633A (is

Inventor

Ferdinand Hermann Bahlmann

Hermann Haller

Original Assignee

Epoplus Gmbh & Co Kg

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-07-26

Filing date

2005-01-06

Publication date

2010-09-15

2005-01-06 Application filed by Epoplus Gmbh & Co Kg filed Critical Epoplus Gmbh & Co Kg

2005-01-06 Publication of IS7633A publication Critical patent/IS7633A/is

2010-09-15 Publication of IS2671B publication Critical patent/IS2671B/is

Links

102000003951 Erythropoietin Human genes 0.000 title 1
108090000394 Erythropoietin Proteins 0.000 title 1
229940105423 erythropoietin Drugs 0.000 title 1
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title 1
210000002889 endothelial cell Anatomy 0.000 abstract 4
210000000056 organ Anatomy 0.000 abstract 3
230000015572 biosynthetic process Effects 0.000 abstract 2
210000004027 cell Anatomy 0.000 abstract 2
230000000694 effects Effects 0.000 abstract 2
230000003511 endothelial effect Effects 0.000 abstract 2
230000004936 stimulating effect Effects 0.000 abstract 2
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 abstract 1
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 abstract 1
101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 abstract 1
101000595923 Homo sapiens Placenta growth factor Proteins 0.000 abstract 1
208000001953 Hypotension Diseases 0.000 abstract 1
102100035194 Placenta growth factor Human genes 0.000 abstract 1
229940123934 Reductase inhibitor Drugs 0.000 abstract 1
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 abstract 1
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
WGUYYUOFQYVTLR-BLPRJPCASA-N [C@@H]1([C@H](O)[C@H](OP(=O)(O)O)[C@@H](COP(=O)(O)OP(=O)(O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O1)N1C=NC=2C(N)=NC=NC12.C(CCCC(=O)O)(=O)OCO Chemical compound [C@@H]1([C@H](O)[C@H](OP(=O)(O)O)[C@@H](COP(=O)(O)OP(=O)(O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O1)N1C=NC=2C(N)=NC=NC12.C(CCCC(=O)O)(=O)OCO WGUYYUOFQYVTLR-BLPRJPCASA-N 0.000 abstract 1
230000002491 angiogenic effect Effects 0.000 abstract 1
230000003257 anti-anginal effect Effects 0.000 abstract 1
230000003178 anti-diabetic effect Effects 0.000 abstract 1
230000003110 anti-inflammatory effect Effects 0.000 abstract 1
230000002402 anti-lipaemic effect Effects 0.000 abstract 1
239000003472 antidiabetic agent Substances 0.000 abstract 1
210000004204 blood vessel Anatomy 0.000 abstract 1
239000011248 coating agent Substances 0.000 abstract 1
238000000576 coating method Methods 0.000 abstract 1
230000004069 differentiation Effects 0.000 abstract 1
210000003709 heart valve Anatomy 0.000 abstract 1
208000021822 hypotensive Diseases 0.000 abstract 1
230000001077 hypotensive effect Effects 0.000 abstract 1
238000000338 in vitro Methods 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
230000005012 migration Effects 0.000 abstract 1
238000013508 migration Methods 0.000 abstract 1
238000012986 modification Methods 0.000 abstract 1
230000004048 modification Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000002243 precursor Substances 0.000 abstract 1
230000035755 proliferation Effects 0.000 abstract 1
230000002792 vascular Effects 0.000 abstract 1
230000004862 vasculogenesis Effects 0.000 abstract 1
230000000982 vasogenic effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1891—Angiogenesic factors; Angiogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Reproductive Health (AREA)
Pulmonology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

IS7633A 2002-07-26 2005-01-06 Rauðkornavaki í undirblóðríkisskömmtum IS2671B (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE10234192A DE10234192B4 (de)	2002-07-26	2002-07-26	Verwendung von Erythropoetin
PCT/EP2003/008229 WO2004012759A2 (de)	2002-07-26	2003-07-25	Erythropoetin zur stimulation endothelialer voläuferzellen

Publications (2)

Publication Number	Publication Date
IS7633A IS7633A (is)	2005-01-06
IS2671B true IS2671B (is)	2010-09-15

Family

ID=30128436

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
IS7633A IS2671B (is)	2002-07-26	2005-01-06	Rauðkornavaki í undirblóðríkisskömmtum
IS8817A IS8817A (is)	2002-07-26	2009-05-06	Rauðkornavaki til örvunar á innanþekju forverafrumum.
IS8909A IS8909A (is)	2002-07-26	2010-07-02	Rauðkornavaki til örvunar á innanþekju forverafrumum.

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
IS8817A IS8817A (is)	2002-07-26	2009-05-06	Rauðkornavaki til örvunar á innanþekju forverafrumum.
IS8909A IS8909A (is)	2002-07-26	2010-07-02	Rauðkornavaki til örvunar á innanþekju forverafrumum.

Country Status (26)

Country	Link
US (4)	US7745387B2 (is)
EP (3)	EP2191838A1 (is)
JP (4)	JP4727988B2 (is)
KR (2)	KR20050026513A (is)
CN (3)	CN101099731B (is)
AT (2)	ATE468132T1 (is)
AU (2)	AU2003255290B2 (is)
BR (1)	BR0312981A (is)
CA (2)	CA2493598A1 (is)
CY (2)	CY1108052T1 (is)
DE (3)	DE10234192B4 (is)
DK (2)	DK1526867T3 (is)
EA (3)	EA200801236A1 (is)
ES (2)	ES2285195T3 (is)
HR (3)	HRP20050065A2 (is)
IL (2)	IL166401A0 (is)
IS (3)	IS2671B (is)
MX (1)	MXPA05001120A (is)
NO (1)	NO20051002L (is)
PL (2)	PL395151A1 (is)
PT (2)	PT1526867E (is)
SG (1)	SG177004A1 (is)
SI (2)	SI1779862T1 (is)
UA (2)	UA94913C2 (is)
WO (1)	WO2004012759A2 (is)
ZA (1)	ZA200500726B (is)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7199102B2 (en) *	2000-08-24	2007-04-03	The Regents Of The University Of California	Orally administered peptides synergize statin activity
US7723303B2 (en)	2000-08-24	2010-05-25	The Regents Of The University Of California	Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
DE10234192B4 (de) *	2002-07-26	2009-11-26	Epoplus Gmbh Co.Kg	Verwendung von Erythropoetin
AU2004262909B2 (en) *	2003-07-29	2010-07-01	Dompe' S.P.A.	Pharmaceutical combination of G-CSF and PlGF useful for blood stem cell
JP4903580B2 (ja) *	2003-12-30	2012-03-28	アウグスティヌス・バーダー	組織再生法
DE102004004509B4 (de) *	2004-01-23	2010-07-01	Epoplus Gmbh Co.Kg	Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
US7579319B2 (en)	2004-12-06	2009-08-25	The Regents Of The University Of California	Methods for improving the structure and function of arterioles
AR053416A1 (es)	2005-11-10	2007-05-09	Protech Pharma S A	Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac
US8128933B2 (en)	2005-11-23	2012-03-06	Acceleron Pharma, Inc.	Method of promoting bone growth by an anti-activin B antibody
EP1973559B1 (en)	2005-11-23	2013-01-09	Acceleron Pharma Inc.	Activin-actriia antagonists and uses for promoting bone growth
NZ573792A (en) *	2006-06-07	2011-09-30	Univ Tokushima	Treatment of ischemic disease using erythropoietin mobilised mononuclear cells
BRPI0717155A2 (pt) *	2006-09-29	2013-10-15	Centocor Ortho Biotech Inc	Agonistas do receptor de epo humana, composições, métodos e usos para prevenção ou tratamento das condições relacionadas á intolerância á glicose
EP3040347A3 (en) *	2006-10-20	2016-09-21	Chugai Seiyaku Kabushiki Kaisha	Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
US8975374B2 (en) *	2006-10-20	2015-03-10	Chugai Seiyaku Kabushiki Kaisha	Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
JP5676849B2 (ja)	2006-10-20	2015-02-25	中外製薬株式会社	抗ｈｂ−ｅｇｆ抗体を有効成分として含む癌治療剤
US8895016B2 (en)	2006-12-18	2014-11-25	Acceleron Pharma, Inc.	Antagonists of activin-actriia and uses for increasing red blood cell levels
CN101610782A (zh) *	2007-01-10	2009-12-23	爱迪生药物公司	使用具有促红细胞生成素或血小板生成素活性的化合物治疗呼吸链紊乱
TW202021980A (zh)	2007-02-02	2020-06-16	美商艾瑟勒朗法瑪公司	衍生自ActRIIB的變體與其用途
AR065613A1 (es) *	2007-03-09	2009-06-17	Chugai Pharmaceutical Co Ltd	Agentes de proteccion para organos transplantados
US20110123481A1 (en) *	2007-08-16	2011-05-26	Remedor Biomed Ltd.	Erythropoietin and fibronectin compositions for therapeutic and cosmetic applications
EA201001814A1 (ru) *	2008-05-22	2011-04-29	Эдисон Фармасьютикалз, Инк.	Лечение митохондриальных заболеваний миметиками эритропоэтина
US8216997B2 (en)	2008-08-14	2012-07-10	Acceleron Pharma, Inc.	Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
ES2949049T3 (es)	2008-08-14	2023-09-25	Acceleron Pharma Inc	Trampas de GDF
CN102482339B (zh)	2009-06-08	2015-06-17	阿塞勒隆制药公司	用于增加产热脂肪细胞的方法
KR20210034684A (ko)	2009-06-12	2021-03-30	악셀레론 파마 인코포레이티드	절두된 ＡｃｔＲＩＩＢ-ＦＣ 융합 단백질
KR102606494B1 (ko) *	2009-08-13	2023-11-24	악셀레론 파마 인코포레이티드	적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용
AU2010322011B2 (en)	2009-11-17	2016-03-31	Acceleron Pharma Inc.	ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
DK2590666T3 (en)	2010-07-06	2017-07-17	Augustinus Bader	TOPICAL APPLICATION OF ERYTHROPOIETIN FOR USE IN THE TREATMENT OF DAMAGE OF THE CORNS
WO2012148200A2 (ko) *	2011-04-26	2012-11-01	아주대학교 산학협력단	허혈성 혈관 질환 치료시술 보조용 조성물
RU2678117C2 (ru)	2012-11-02	2019-01-23	Селджин Корпорейшн	Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
US8992951B2 (en)	2013-01-09	2015-03-31	Sapna Life Sciences Corporation	Formulations, procedures, methods and combinations thereof for reducing or preventing the development, or the risk of development, of neuropathology as a result of trauma
CN110075355A (zh) *	2013-10-22	2019-08-02	康斯瓦维有限责任公司	用于抑制支架型心瓣膜或生物假体的狭窄、阻塞或钙化的方法
BR112016029226A2 (pt)	2014-06-13	2017-10-17	Acceleron Pharma Inc	métodos e composições para o tratamento de úlceras
AU2016218977C1 (en) *	2015-02-13	2023-03-23	Factor Bioscience Inc.	Nucleic acid products and methods of administration thereof
CN105233256A (zh) *	2015-10-28	2016-01-13	中国人民解放军第三军医大学	促红细胞生成素及其衍生物在制备治疗疾病中促进凋亡细胞清除的药物中的应用
US11534466B2 (en) *	2016-03-09	2022-12-27	Aal Scientifics, Inc.	Pancreatic stem cells and uses thereof
GB2550114A (en) *	2016-05-03	2017-11-15	Kymab Ltd	Methods, regimens, combinations & antagonists
IL308824A (en)	2016-08-17	2024-01-01	Factor Bioscience Inc	Nucleic acid products and methods of administration thereof
CN108114282B (zh) *	2016-11-28	2021-03-02	北京大学第三医院	他汀类化合物治疗缺血性疾病的用途
EP3620531A4 (en)	2017-05-02	2021-03-17	National Center of Neurology and Psychiatry	METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
WO2019078344A1 (ja) *	2017-10-20	2019-04-25	学校法人兵庫医科大学	抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
RU2678768C1 (ru) *	2018-09-25	2019-02-01	Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ")	Способ профилактики ишемически-реперфузионных повреждений почек карбамилированным дарбэпоэтином в эксперименте
RU2695334C1 (ru) *	2018-09-25	2019-07-23	Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ")	Способ профилактики нарушений функций почек карбамилированным дарбэпоэтином в эксперименте
AU2020301036A1 (en)	2019-07-03	2022-02-17	Factor Bioscience Inc.	Cationic lipids and uses thereof
US10501404B1 (en)	2019-07-30	2019-12-10	Factor Bioscience Inc.	Cationic lipids and transfection methods
EP4221736A4 (en)	2020-10-02	2025-03-05	Keros Therapeutics, Inc.	Methods of using activin receptor type ii variants
CN119080909A (zh) *	2024-08-29	2024-12-06	深圳赛保尔生物药业有限公司	负载peg-epo及间充质干细胞的组合物、药物及其制备方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ210501A (en)	1983-12-13	1991-08-27	Kirin Amgen Inc	Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
IL77081A (en)	1984-12-04	1999-10-28	Genetics Inst	Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
US4732889A (en)	1985-02-06	1988-03-22	Chugai Seiyaku Kabushiki Kaisha	Pharmaceutical composition for the treatment of the anemia of rheumatoid arthritis
JPH0764742B2 (ja)	1985-11-27	1995-07-12	ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド	Ａｉｄｓ型疾患治療用組成物
US5198417A (en) *	1985-11-27	1993-03-30	Genetics Institute, Inc.	Methods of treating pancytopenia and AIDS by co-administering EPO and colony stimulating factors
DK173067B1 (da)	1986-06-27	1999-12-13	Univ Washington	Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
US5013718A (en)	1986-11-21	1991-05-07	Amgen, Inc.	Method for treating iron overload using EPO
DE3729863A1 (de) *	1987-09-05	1989-03-16	Boehringer Mannheim Gmbh	Stabilisierte erythropoietin-lyophilisate
EP0424386A1 (en) *	1988-02-24	1991-05-02	American National Red Cross	Device for site directed neovascularization and method for same
US5024841A (en) *	1988-06-30	1991-06-18	Collagen Corporation	Collagen wound healing matrices and process for their production
DE4014654A1 (de)	1990-05-08	1991-11-14	Behringwerke Ag	Galenische waessrige formulierungen von erythropoietin und ihre verwendung
DK0575555T3 (da) *	1991-03-11	2001-11-05	Curis Inc	Proteininduceret morfogenese
US5354934A (en) *	1993-02-04	1994-10-11	Amgen Inc.	Pulmonary administration of erythropoietin
AU697453B2 (en)	1993-04-29	1998-10-08	Abbott Laboratories	Erythropoietin analog compositions and methods
ZA946122B (en)	1993-08-17	1995-03-20	Amgen Inc	Erythropoietin analogs
JPH08205860A (ja) *	1994-01-21	1996-08-13	Usa Government	造血細胞の膨大化および移植方法
ITFI940106A1 (it) *	1994-05-27	1995-11-27	Menarini Ricerche Sud Spa	Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica
ATE251912T1 (de)	1994-11-03	2003-11-15	Roche Diagnostics Gmbh	Verwendung des erythropoietins zur behandlung von rheumatoider arthritis
US5837675A (en) *	1995-02-03	1998-11-17	Brox; Alan G.	Synergistic effect of insulin-like growth factor-I and erythropoietin
US20020052309A1 (en) *	1996-09-11	2002-05-02	Athanasius A. Anagnostou	Method of treating endothelial injury
US5980887A (en) *	1996-11-08	1999-11-09	St. Elizabeth's Medical Center Of Boston	Methods for enhancing angiogenesis with endothelial progenitor cells
US6284260B1 (en)	1998-02-04	2001-09-04	Veronica L. Zaharia Czeizler	Treatment with erythropoietin of bleeding from benign and malignant lesions with normal and abnormal coagulation parameters
US6274158B1 (en) *	1998-02-04	2001-08-14	Veronica L. Zaharia Czeizler	Treatment with recombinant human erythropoietin of bleeding in patients with normal and abnormal hemostasis
DE19857609A1 (de)	1998-12-14	2000-06-15	Hannelore Ehrenreich	Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
CA2383940A1 (en) *	1999-04-13	2000-10-19	The Kenneth S. Warren Laboratories, Inc.	Modulation of excitable tissue function by peripherally administered erythropoietin
CA2407797A1 (en)	2000-05-02	2001-11-08	Action Pharma Aps	Methods for treatment of diseases associated with inflammation under non-ischemic conditions
US7259146B2 (en) *	2000-05-26	2007-08-21	Ortho-Mcneil Pharmaceutical, Inc.	Neuroprotective peptides
US7078376B1 (en) *	2000-08-11	2006-07-18	Baxter Healthcare S.A.	Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
US20020065214A1 (en) *	2000-11-29	2002-05-30	Adrian Iaina	Method of treating congestive heart failure
PA8536201A1 (es)	2000-12-29	2002-08-29	Kenneth S Warren Inst Inc	Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
IL158261A0 (en)	2001-04-04	2004-05-12	Genodyssee	New polynucleotides and polypeptides of the erythropoietin gene
US6784154B2 (en) *	2001-11-01	2004-08-31	University Of Utah Research Foundation	Method of use of erythropoietin to treat ischemic acute renal failure
CA2468499A1 (en) *	2001-11-28	2003-06-05	Ortho-Mcneil Pharmaceutical, Inc.	Erythropoietin dosing regimen for treating anemia
CN1612747A (zh) *	2002-01-09	2005-05-04	克鲁塞尔荷兰公司	促红细胞生成素在预防或治疗心力衰竭中的用途
US6748154B2 (en) *	2002-03-28	2004-06-08	Nortel Networks Limited	Optical module access tray
DE10234192B4 (de)	2002-07-26	2009-11-26	Epoplus Gmbh Co.Kg	Verwendung von Erythropoetin
DE102004004509B4 (de) *	2004-01-23	2010-07-01	Epoplus Gmbh Co.Kg	Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden

2002
- 2002-07-26 DE DE10234192A patent/DE10234192B4/de not_active Expired - Fee Related
2003
- 2003-07-25 EA EA200801236A patent/EA200801236A1/ru unknown
- 2003-07-25 ES ES03766302T patent/ES2285195T3/es not_active Expired - Lifetime
- 2003-07-25 EP EP10000381A patent/EP2191838A1/de not_active Withdrawn
- 2003-07-25 AT AT07001689T patent/ATE468132T1/de not_active IP Right Cessation
- 2003-07-25 SI SI200331837T patent/SI1779862T1/sl unknown
- 2003-07-25 EP EP07001689A patent/EP1779862B1/de not_active Expired - Lifetime
- 2003-07-25 PT PT03766302T patent/PT1526867E/pt unknown
- 2003-07-25 MX MXPA05001120A patent/MXPA05001120A/es active IP Right Grant
- 2003-07-25 PL PL395151A patent/PL395151A1/pl unknown
- 2003-07-25 EA EA200500281A patent/EA009463B1/ru not_active IP Right Cessation
- 2003-07-25 JP JP2004525322A patent/JP4727988B2/ja not_active Expired - Fee Related
- 2003-07-25 CN CN200710127913XA patent/CN101099731B/zh not_active Expired - Fee Related
- 2003-07-25 HR HR20050065A patent/HRP20050065A2/hr not_active Application Discontinuation
- 2003-07-25 SI SI200330881T patent/SI1526867T1/sl unknown
- 2003-07-25 WO PCT/EP2003/008229 patent/WO2004012759A2/de not_active Ceased
- 2003-07-25 HR HR20070189A patent/HRP20070189A2/xx not_active Application Discontinuation
- 2003-07-25 CN CN2007101279144A patent/CN101099860B/zh not_active Expired - Fee Related
- 2003-07-25 UA UAA200801307A patent/UA94913C2/ru unknown
- 2003-07-25 AT AT03766302T patent/ATE360436T1/de not_active IP Right Cessation
- 2003-07-25 ES ES07001689T patent/ES2345673T3/es not_active Expired - Lifetime
- 2003-07-25 DK DK03766302T patent/DK1526867T3/da active
- 2003-07-25 CA CA002493598A patent/CA2493598A1/en not_active Abandoned
- 2003-07-25 DK DK07001689.4T patent/DK1779862T3/da active
- 2003-07-25 KR KR1020057001341A patent/KR20050026513A/ko not_active Ceased
- 2003-07-25 CA CA2710100A patent/CA2710100A1/en not_active Abandoned
- 2003-07-25 EP EP03766302A patent/EP1526867B1/de not_active Expired - Lifetime
- 2003-07-25 CN CNA038221160A patent/CN1681526A/zh active Pending
- 2003-07-25 HR HR20100187A patent/HRP20100187A2/xx not_active Application Discontinuation
- 2003-07-25 DE DE50312729T patent/DE50312729D1/de not_active Expired - Lifetime
- 2003-07-25 EA EA200700196A patent/EA013966B1/ru not_active IP Right Cessation
- 2003-07-25 UA UAA200501760A patent/UA85997C2/ru unknown
- 2003-07-25 SG SG2007003890A patent/SG177004A1/en unknown
- 2003-07-25 PT PT07001689T patent/PT1779862E/pt unknown
- 2003-07-25 BR BR0312981-0A patent/BR0312981A/pt not_active IP Right Cessation
- 2003-07-25 KR KR1020107011097A patent/KR20100077033A/ko not_active Ceased
- 2003-07-25 PL PL03374874A patent/PL374874A1/xx unknown
- 2003-07-25 US US10/522,426 patent/US7745387B2/en not_active Expired - Fee Related
- 2003-07-25 DE DE50307140T patent/DE50307140D1/de not_active Expired - Lifetime
- 2003-07-25 AU AU2003255290A patent/AU2003255290B2/en not_active Ceased
2005
- 2005-01-06 IS IS7633A patent/IS2671B/is unknown
- 2005-01-20 IL IL16640105A patent/IL166401A0/xx not_active IP Right Cessation
- 2005-01-25 ZA ZA200500726A patent/ZA200500726B/xx unknown
- 2005-02-24 NO NO20051002A patent/NO20051002L/no not_active Application Discontinuation
2007
- 2007-07-02 CY CY20071100871T patent/CY1108052T1/el unknown
2009
- 2009-02-25 AU AU2009200748A patent/AU2009200748A1/en not_active Abandoned
- 2009-05-06 IS IS8817A patent/IS8817A/is unknown
2010
- 2010-03-18 IL IL204577A patent/IL204577A/en not_active IP Right Cessation
- 2010-04-13 US US12/759,275 patent/US20100247450A1/en not_active Abandoned
- 2010-04-13 US US12/759,321 patent/US20100247452A1/en not_active Abandoned
- 2010-04-13 US US12/759,299 patent/US20100247451A1/en not_active Abandoned
- 2010-07-02 IS IS8909A patent/IS8909A/is unknown
- 2010-07-09 JP JP2010157094A patent/JP2010280672A/ja not_active Withdrawn
- 2010-07-09 JP JP2010157093A patent/JP2010280671A/ja not_active Withdrawn
- 2010-07-09 JP JP2010157092A patent/JP2010280670A/ja not_active Withdrawn
- 2010-07-29 CY CY20101100712T patent/CY1110713T1/el unknown

Also Published As

Publication number	Publication date
PT1526867E (pt)	2007-07-09
SI1779862T1 (sl)	2010-09-30
PT1779862E (pt)	2010-08-18
NO20051002L (no)	2005-04-18
US20100247450A1 (en)	2010-09-30
SI1526867T1 (sl)	2007-10-31
EA200500281A1 (ru)	2005-06-30
DK1779862T3 (da)	2010-08-16
JP2010280670A (ja)	2010-12-16
WO2004012759A2 (de)	2004-02-12
JP4727988B2 (ja)	2011-07-20
EP1526867A2 (de)	2005-05-04
CA2493598A1 (en)	2004-02-12
AU2009200748A1 (en)	2009-03-19
DE10234192A1 (de)	2004-02-12
KR20050026513A (ko)	2005-03-15
US20100247451A1 (en)	2010-09-30
SG177004A1 (en)	2012-01-30
CN101099731B (zh)	2011-02-16
IL204577A (en)	2012-08-30
ATE360436T1 (de)	2007-05-15
BR0312981A (pt)	2005-06-14
WO2004012759A3 (de)	2004-06-03
CY1110713T1 (el)	2015-06-10
ATE468132T1 (de)	2010-06-15
CN101099860A (zh)	2008-01-09
UA94913C2 (ru)	2011-06-25
IS7633A (is)	2005-01-06
HRP20050065A2 (en)	2005-10-31
IL166401A0 (en)	2006-01-15
DK1526867T3 (da)	2007-09-17
EP2191838A1 (de)	2010-06-02
EA200801236A1 (ru)	2009-02-27
PL374874A1 (en)	2005-11-14
JP2010280671A (ja)	2010-12-16
DE50312729D1 (de)	2010-07-01
CN101099731A (zh)	2008-01-09
CN1681526A (zh)	2005-10-12
US7745387B2 (en)	2010-06-29
EP1779862B1 (de)	2010-05-19
AU2003255290B2 (en)	2009-04-09
JP2010280672A (ja)	2010-12-16
IS8817A (is)	2009-05-06
ES2285195T3 (es)	2007-11-16
ZA200500726B (en)	2006-06-28
JP2006503001A (ja)	2006-01-26
EP1779862A1 (de)	2007-05-02
EA200700196A1 (ru)	2007-04-27
HRP20070189A2 (en)	2007-07-31
PL395151A1 (pl)	2011-08-16
WO2004012759B1 (de)	2004-07-08
AU2003255290A1 (en)	2004-02-23
US20100247452A1 (en)	2010-09-30
MXPA05001120A (es)	2005-08-03
HRP20100187A2 (hr)	2010-08-31
IS8909A (is)	2010-07-02
CA2710100A1 (en)	2004-02-12
UA85997C2 (en)	2009-03-25
EA009463B1 (ru)	2007-12-28
DE10234192B4 (de)	2009-11-26
HK1081841A1 (en)	2006-05-26
DE50307140D1 (en)	2007-06-06
KR20100077033A (ko)	2010-07-06
EA013966B1 (ru)	2010-08-30
EP1526867B1 (de)	2007-04-25
HK1108625A1 (zh)	2008-05-16
US20050272634A1 (en)	2005-12-08
CY1108052T1 (el)	2013-09-04
ES2345673T3 (es)	2010-09-29
CN101099860B (zh)	2011-06-01

Publication	Publication Date	Title
IS2671B (is)	2010-09-15	Rauðkornavaki í undirblóðríkisskömmtum
Mirhoseini et al.	1983	Myocardial revascularization by laser: a clinical report
Yu et al.	1997	Effects of photostimulation on wound healing in diabetic mice
DE3880318D1 (de)	1993-05-19	Polypeptide mit kollagen typ iv aktivitaet.
ATE469654T1 (de)	2010-06-15	Verwendung des erythropoietins zur regeneration von lebergewebe
DE58905850D1 (de)	1993-11-11	Katheter für die perkutane gefäss- und organchirurgie mittels energiestrahlung.
US20100261957A1 (en)	2010-10-14	Cardiac wall tension relief with cell loss management
Salasche et al.	1983	Keloids of the earlobes: a surgical technique
WO2003057820A3 (en)	2003-12-04	Peptide activators of vegf
ES2162331T3 (es)	2001-12-16	Utilizacion del factor de crecimiento del tejido nervioso para conservacion, cultivo o tratamiento de la cornea.
AU754874B2 (en)	2002-11-28	A method for inducing production of growth factors
NO20021410L (no)	2002-05-24	Forebygging og behandling av blodkoagulasjons-relaterte sykdommer
Yamaguchi et al.	2005	Skin grafting: surgical techniques
RU2279879C2 (ru)	2006-07-20	Способ интраоперационной подготовки лучевой артерии в качестве аортокоронарного шунта
Bocchi et al.	1995	Pathological scar formation in burns: new biochemical and molecular factors in the healing process
Senges et al.	1983	Effect of brief periods of paced ventricular tachycardia on coronary blood flow in dogs before and after graded coronary stenosis
Karba et al.	1995	Promotion of wound healing by electrical stimulation
Howes	1985	The latest wrinkles in wound healing
Sanchez	1990	Cultivo in vitro de epidermis.
RU93037867A (ru)	1996-03-20	Способ лечения длительно незаживающих ран и трофических язв кожных покровов
JPS6442441A (en)	1989-02-14	Macrophage activator
IT1203815B (it)	1989-02-23	Esteri polisaccaridici e loro sali